Corise Pimocard 5 mg is a high-strength, prescription-only veterinary cardiovascular medication formulated for the clinical management and treatment of advanced congestive heart failure (CHF) and structural heart disease in dogs and cats. The active pharmaceutical ingredient, Pimobendan (5 mg), functions as a highly effective "inodilator" that delivers a crucial dual mechanism of action: it operates as a calcium sensitizer to directly improve heart muscle contractility (positive inotropy) while simultaneously acting as a phosphodiesterase III (PDE3) inhibitor to dilate peripheral blood vessels.

This targeted action minimizes resistance in systemic blood pathways, reduces the afterload and overall workload on weak heart chambers, and optimizes total cardiac output without increasing oxygen consumption. In canine patients, Pimocard 5 mg is a mainstay treatment for medium to large-sized breeds suffering from congestive heart failure secondary to Dilated Cardiomyopathy (DCM) or Atrioventricular Valvular Insufficiency (AVVI/MMVD). It is also prescribed in preclinical stages (such as Stage B2) to delay the onset of clinical heart failure in cases with confirmed cardiac enlargement. In feline healthcare, it serves under strict veterinary discretion for advanced myocardial pathologies showing systolic dysfunction. Presented as palatable chewable tablets, it significantly eases debilitating clinical symptoms like chronic coughing, breathlessness, and lethargy, substantially boosting everyday stamina and quality of life.